华润双鹤子公司波生坦分散片获得药品注册证书

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, China Resources Double Crane Limin Pharmaceutical (济南) Co., Ltd., has received the drug registration certificate for Bosentan dispersible tablets from the National Medical Products Administration (国家药监局) [1] Group 1: Product Information - Bosentan dispersible tablets are indicated for pulmonary arterial hypertension (PAH) classified as WHO Group 1 [1] - The drug is intended to improve pulmonary vascular resistance (PVR) in pediatric patients aged 3 years and older with idiopathic or congenital PAH [1] - It is also used for the treatment of adult patients with WHO functional class II to IV pulmonary arterial hypertension (PAH) [1]